NCT05779579View on ClinicalTrials.gov

Study of HS-10517 in Chinese Adult Participants

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

340

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions
COVID-19
Interventions
DRUG

HS-10517 Dose 1

HS-10517 Dose 1+Ritonavir

DRUG

HS-10517 Dose 2

HS-10517 Dose 2+Ritonavir

DRUG

HS-10517 Dose 3

HS-10517 Dose 3+Ritonavir

DRUG

HS-10517 Dose 4

HS-10517 Dose 4+Ritonavir

DRUG

Placebo

Dose level A of placebo

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Shandong First Medical University Shandong Provincial Qianfoshan Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

NCT05779579 - Study of HS-10517 in Chinese Adult Participants | Biotech Hunter | Biotech Hunter